✦ LIBER ✦

How valid is disease-free survival as an endpoint in adjutant trials

✍ Scribed by Carter, Stephen K.

Book ID: 123213740
Publisher: Elsevier Science
Year: 1980
Tongue: English
Weight: 146 KB
Volume: 1
Category: Article
ISSN: 0197-2456
DOI: 10.1016/0197-2456(80)90059-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of progression-free survival as a va

Use of progression-free survival as a valid endpoint in phase II cancer clinical trials

✍ Maurie Markman 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 86 KB

How valid is dopamine transporter imagin

How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?

✍ Paul K. Morrish 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

To use functional imaging data as indices of disease progression, it is essential that methods are valid. It is not possible for that validation to come from pathology and the methods can only gain validity from the relationship to clinical indices of progression. Validity as a measurement of diseas

PCN63 META-ANALYTIC, TRIAL-LEVEL APPROAC

PCN63 META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER

✍ R Miksad; V Zietemann; R Mattheucci Gothe; R Schwarzer; A Conrads-Frank; P Schne 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Disease-free survival as an end-point in

Disease-free survival as an end-point in the treatment of solid tumours – Perspectives from clinical trials and clinical practice

✍ Robinson, Andrew G.; Booth, Christopher M.; Eisenhauer, Elizabeth A. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 326 KB

Validation of serum C-reactive protein (

Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)

✍ de Martino, Michela; Klatte, Tobias; Seemann, Christoph; Waldert, Matthias; Hait 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Minimal Residual Disease Quantification

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

✍ Bottcher, S.; Ritgen, M.; Fischer, K.; Stilgenbauer, S.; Busch, R. M.; Fingerle- 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 272 KB